Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) – For an in-depth report on Ariad Pharmaceuticals Inc. follow: www.BullTrends.com/stockquote/ARIA
Ariad Pharmaceuticals closed down 4.49% on about 14.5 million shares traded on Monday. The stock was one of the biggest decliners on the NASDAQ despite any news from the company. Last month the company announced that it has initiated a phase II pivotal study that will evaluate the safety and efficacy of AP26113 in locally advanced or metastatic non-small cell lung cancer in patients who had previously been treated with Pfizer’s (PFE) Xalkori (crizotinib). A couple of articles regarding Ariad being a potential buyout candidate have surfaced.
Mallinckrodt plc (NYSE: MNK) - For an in-depth report on Mallinckrodt plc follow: www.BullTrends.com/stockquote/MNK
Shares of MNK closed down 2.51% on about 23.6 million shares traded. The stock had a huge volume advance on Monday after it was revealed that the company will buy drugmaker Questcor Pharmaceuticals Inc for about $5.6 billion to gain access to its multiple sclerosis drug, Acthar Gel, which is set to hit sales of $1 billion this year.
Amazonica, Corp. (OTCBB: AMZZ) - For an in-depth report on Amazonica, Corp. follow: www.BullTrends.com/stockquote/AMZZ
Shares of AMZZ closed down 7.50% on Monday with about 7.8 million shares traded. The stock was one of the biggest decliners in the OTCBB market. The company announced that it has recently added an upgrade to it previously submitted patent application for the manufacture of ultra-pure hydrogen.
Tesla Motors, Inc. (NASDAQ: TSLA) - For an in-depth report on Tesla Motors, Inc. follow: www.BullTrends.com/stockquote/TSLA
Shares of TSLA closed down 2.22% on about 9.9 million shares traded on Monday. RW Baird believes Tesla’s recent pull back could be due to the market pricing in the potential for weak results. Baird sees Tesla’s gigafactory site selection, partner announcements, the marketing campaign for the ModelX, and updates on global trends as upcoming catalysts. Shares have been given an Outperform rating with a $275 price target.
Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.